### **EXANE BNP PARIBAS**

## **Luxury Goods**

Valuation Sheet, Estimates & Performance

# Luxury Goods: Valuation Summary

Automobiles	(08 Ja	\	Price		(EURm)	P/E (x)			EV/Sales (x)			EV/Restated EBITDA (x)				(x)		FCF yield (%)			ROCE incl. gdw (%)				EV/CE (x)	
Automobiles		n 16)		(%)	(LOKIII)	CY15		CY17	CY15		CY17	CY15		CY17	CY15		CY17	CY15	CY16	CY17	CY15	٠, ,	CY17	CY15		CY17
				9		29.8	22.2	18.8	3.3	2.8	2.6	15.6	12.2	10.4	21.1	15.4	12.5	1.9	4.2	5.4	17.1	19.9	23.6	5.4	4.6	4.4
Ferrari (-)	USD	43.1	47.0	9	7,498	29.8	22.2	18.8	3.3	2.8	2.6	15.6	12.2	10.4	21.1	15.4	12.5	1.9	4.2	5.4	17.1	19.9	23.6	5.4	4.6	4.4
Footwear				-4		56.0	23.7	20.6	1.0	0.9	0.9	12.8	9.0	8.1	28.3	13.6	11.7	4.1	1.0	3.5	6.5	12.8	14.1	2.8	2.6	2.5
GEOX (-)	EUR	3.7	3.5	-4	947	56.0	23.7	20.6	1.0	0.9	0.9	12.8	9.0	8.1	28.3	13.6	11.7	4.1	1.0	3.5	6.5	12.8	14.1	2.8	2.6	2.5
Sporting Goods				26		48.5	36.1	27.9	2.2	1.8	1.6	19.5	15.7	12.9	25.7	20.4	16.4	2.1	2.1	2.8	10.4	10.9	11.9	2.1	2.2	2.1
adidas (+)	EUR	83.5	105.0	26	16,141	21.4	21.5	18.2	0.9	0.9	0.9	10.6	10.8	9.5	13.8	14.0	12.0	2.1	2.1	2.8	10.4	10.9	11.9	2.1	2.2	2.1
Nike B (NR)	USD	58.9			81,100	25.7	23.8	20.6	2.5	2.4	2.2	15.4	14.2	12.4	17.8	16.2	14.1									
Puma (NR)	EUR	183.2			2,673	65.4	44.4	28.9	0.7	0.7	0.6	15.3	12.6	9.7	25.6	19.7	13.9									
Under Armour, Inc. Class A (NR)	USD	75.0			14,271	81.4	55.0	43.7	4.8	3.3	2.7	36.7	25.2	20.2	45.8	31.7	25.6									
Specialty Retailers				-12		18.9	14.9	15.5	1.1	0.9	0.9	9.2	7.3	6.7	12.6	12.4	10.4	3.6	3.8	4.2	32.5	34.7	36.8	7.7	8.5	8.3
Grandvision (=)	EUR	26.1	23.0	-12	6,638	26.4	26.8	24.4	2.1	2.2	2.1	13.1	13.6	12.4	17.0	17.5	16.0	3.6	3.8	4.2	32.5	34.7	36.8	7.7	8.5	8.3
J.C. Penney Company, Inc (NR)	USD	7.2			1,987	NC	NC	23.6	0.5	0.5	0.4	10.3	6.8	5.4	NS	19.7	11.9									
,	USD	47.9			7,846	13.9	10.4	9.8	0.8	0.6	0.6	6.0	4.7	4.6	9.4	7.4	7.3									
, ,	USD	35.9			10,065	14.9	9.4	8.4	1.0	0.7	0.7	7.5	5.3	5.2	10.9	8.1	7.7									
Nordstrom, Inc. (NR)	USD	46.2			7,433	20.3	12.8	11.5	1.1	0.7	0.7	9.0	6.0	5.8	13.0	9.1	8.9									
Soft Luxury				25		30.4	20.6	16.8	2.8	2.2	2.0	13.1	9.9	8.7	20.3	14.3	11.8	3.5	5.0	5.6	23.3	24.5	25.4	5.3	4.3	4.0
Brunello Cucinelli (-)	EUR	14.9	14.0	-6	1,015	34.9	27.9	25.7	3.0	2.4	2.1	17.5	13.8	12.3	24.2	19.3	17.2	(1.1)	0.8	2.3	13.9	13.7	14.3	4.8	3.8	3.5
Burberry (=)	GBP	11.0	14.5	32	6,465	14.8	14.4	13.7	1.7	1.6	1.5	7.6	7.2	6.6	9.7	9.1	8.4	5.5	5.7	6.0	37.1	35.5	34.9	4.7	4.2	3.8
, , , ,	USD	32.0			7,898	18.6	15.1	13.6	2.0	1.7	1.6	9.4	7.4	6.7	12.1	9.4	8.5									
` '	EUR	301.5	309.0	3	31,432	33.2	28.3	25.7	6.6	5.6	4.9	18.4	15.3	13.5	20.9	17.4	15.3	2.8	3.3	3.7	42.6	45.3	48.7	13.3	11.7	11.1
3 ( )	EUR	70.0	103.0	47	4,828	19.7	12.8	12.4	2.6	1.7	1.6	11.7	7.7	7.4	15.1	9.9	9.5	3.3	6.0	6.3	31.4	30.4	29.6	6.2	3.9	3.7
` '	GBP	1.2			547	29.9	18.0	14.8	2.3	1.5	1.3	14.3	8.7	7.2	21.9	13.4	11.3									
3()	EUR	143.0	196.0	37	18,000	17.0	12.7	11.2	2.3	1.9	1.7	12.2	9.4	8.3	14.6	11.1	9.7	4.6	6.3	7.3	8.0	8.8	9.6	1.4	1.2	1.1
. ,	EUR	135.4	176.0	30	67,852	20.4	15.6	14.6	2.5	2.1	1.9	10.5	8.2	7.6	13.5	10.4	9.5	4.7	6.6	7.0	11.1	12.2	12.8	2.2	1.9	1.8
3 ( )	USD	37.8	400		6,186	12.0	8.6	8.1	2.0	1.3	1.2	6.9	4.6	4.5	7.9	5.3	5.0									
. ,	EUR	12.4	16.0	30	3,088	23.0	15.9	14.8	4.6	3.1	2.7	13.5	9.2	8.2	15.6	10.5	9.3	3.5	5.3	5.9	27.6	30.7	31.9	6.4	4.8	4.4
	GBP	9.6	00.0	0.4	752	147.0	75.4	38.9	3.3	3.2	2.8	32.6	26.1	19.5	92.5	57.6	34.9	4.0	- 0		44.0	40.4	40.0	4.0	4.0	4.7
	HKD	21.3	28.0	31	6,464	16.5	14.7	13.5	1.7	1.7	1.6	7.3	6.6	5.9	10.9	9.6	8.7	4.6	5.8	6.3	11.8	13.1	13.9	1.9	1.8	1.7
,	USD EUR	103.6 20.0	27.0	35	7,970	18.7 26.8	13.3 18.1	11.8 17.2	1.4 3.1	1.1 2.2	1.0 2.0	8.9 14.3	6.8 9.5	6.3 8.9	11.9	9.0	8.1 10.9	3.1	E 1	E 7	34.4	38.4	40.0	0.0	6.6	6.4
ŭ (,	EUR	69.1	74.0	35 7	3,367 2,114	24.2	17.6	16.4	2.3	1.7	1.6	11.8	9.5 8.4	7.7	17.8 15.4	11.8 10.8	9.9	3.7	5.1 5.1	5.7 5.4	15.1	16.8	40.2 17.5	8.9 3.4	6.6 2.6	6.4 2.5
· · ·	LUIN	03.1	74.0	•	2,114																					
Hard Luxury Chow Tai Fook Jewellery Group Ltd (NR)	HKD	4.7		40	5.708	<b>16.4</b> 18.7	<b>11.5</b> 10.5	<b>10.1</b> 9.5	<b>1.5</b> 1.3	<b>1.3</b> 0.8	<b>1.1</b> 0.7	<b>9.2</b> 14.1	<b>6.6</b> 7.8	<b>5.7</b> 6.9	<b>11.3</b> 16.2	<b>7.8</b> 9.1	<b>6.6</b> 8.0	4.0	6.5	6.1	18.2	19.3	20.0	2.6	2.3	2.1
, , , ,	HKD	0.2			148	23.3	NC	9.5	0.2	0.6	0.7	7.4	7.0	6.9	11.8	9.1	0.0									
, , , ,	HKD	1.0			582	11.8	8.7	7.7	0.2	0.3	0.3	5.9	4.1	3.6	7.0	4.9	4.2									
3 3 1 7	HKD	15.2			1.030	10.6	6.9	6.2	0.4	0.4	0.4	6.8	3.8	3.0	7.5	4.1	3.2									
, ,	CHF	66.1	91.0	38	34,278	16.1	15.0	13.8	2.6	2.4	2.2	9.6	8.5	7.7	11.5	10.2	9.1	4.5	5.6	6.1	24.9	26.0	26.9	3.5	3.2	2.9
	CHF	315.0	448.0	42	15,750	16.9	12.2	11.4	2.3	1.6	1.5	10.2	7.1	6.3	12.2	8.5	7.4	3.5	7.4	6.0	11.6	12.7	13.0	1.8	1.3	1.2
/	USD	68.3			7,724	17.3	15.9	12.8	2.5	2.0	1.6	10.3	8.0	6.6	12.8	9.8	7.9	0.0	•••	0.5	5					
Eyewear				5	,	27.4	19.1	21.1	1.9	1.7	1.6	11.1	8.9	8.5	15.2	11.6	11.8	3.5	3.9	4.5	16.1	17.2	19.2	4.6	4.4	4.4
•	EUR	57.0	60.0	5	27,105	29.5	26.1	23.1	3.2	2.9	2.6	14.5	12.8	11.4	18.4	16.3	14.4	3.5	3.9	4.5	16.1	17.2	19.2	4.6	4.4	4.4
` '	EUR	9.8	00.0	J	594	25.4	12.0	19.1	0.7	0.5	0.5	7.6	4.9	5.7	12.0	7.0	9.3	0.0	0.0	5				5		1
Average ratio				21		28.9	20.2		2.1	1.7	1.6	12.4	9.6	8.4	18.1	13.4		3.4	4.6	5.2	20.7	22.3	23.5	4.8	4.1	3.9

## Luxury Goods: Estimates & Performance

		EPS Account Currency			EPS Growth (%)			EPS to Cons. (Thomson Reuters) (%)			Organic sales growth (%)			EBIT Margin (%)				sted net o		Adjusted net debt/EBITDA (x)			Performance EUR (%)		
	y/e		CY16	CY17	CY15	CY16	CY17	FY15	FY16	, , ,	CY15		CY17	CY15		CY17	FY15	FY16	FY17		CY16	` '	3m	12m	YTD
Automobiles																			<u>'</u>						
Ferrari (-)	Dec.	1.50	1.79	2.11	+9.8	+19.3	+17.9	-2.0	+6.7	+10.5				15.8	17.9	21.0	790	570	286	1.3	0.9	0.4			-10.0
Footwear																									
GEOX (-)	Dec.	0.06	0.15	0.18	NS	+146.6	+15.1	+9.7	+19.5	-6.1	+7.9	+10.4	+6.1	3.5	6.9	7.4	(24)	(28)	(49)	(0.3)	(0.3)	(0.4)	-6.7	+37.7	-10.5
Sporting Goods																									
adidas (+)	Dec.	3.41	3.89	4.57	+14.6	+13.9	+17.6	-2.4	-2.4	-1.5	+8.1	+7.6	+6.9	6.5	6.6	7.1	595	951	1,216	0.4	0.6	0.7	+10.9	+48.6	-7.2
Nike B (NR)	Dec.	2.15	2.48	2.86	+132.0	+15.4	+15.3							14.0	15.1	15.6							-2.2	+32.4	-5.6
Puma (NR)	Dec.	2.70	4.13	6.33	-37.1	+52.9	+53.4							2.8	3.3	4.4							-5.3	+8.8	-7.8
Under Armour, Inc. Class A (NR)	Dec.	1.05	1.36	1.72	+10.3	+30.2	+25.7							10.5	10.4	10.4							-23.2	+19.0	-6.7
Specialty Retailers																									
Grandvision (=)	Dec.	0.87	0.98	1.07	+20.6	+11.6	+9.9	-2.2	-3.0	-4.2	+5.5	+4.4	+4.4	12.3	12.7	12.9	738	520	320	1.4	0.9	0.5	+11.1		-5.5
J.C. Penney Company, Inc (NR)	Dec.	(1.21)	(0.33)	0.30	+54.8	+73.0	NS							0.4	2.3	3.7							-22.8	-2.3	+7.9
Kohl's Corp (NR)	Dec.	4.31	4.61	4.91	+1.6	+7.0	+6.4							8.6	8.4	8.3							+7.1	-13.8	+0.8
Macy's Inc (NR)	Dec.	3.99	3.81	4.25	-9.4	-4.6	+11.7							8.9	8.3	8.7							-27.3	-41.6	+2.8
Nordstrom, Inc. (NR)	Dec.	3.39	3.60	4.03	-9.0	+6.3	+12.0							8.3	7.7	7.6							-30.2	-31.8	-6.9
Soft Luxury																									
Brunello Cucinelli (-)	Dec.	0.49	0.53	0.58	+0.7	+9.1	+8.5	+0.0	-2.8	-7.5	+9.4	+10.5	+9.5	12.3	12.2	12.4	63	65	53	0.9	0.8	0.6	-12.1	-14.3	-8.5
Burberry (=)	Mar.	0.74	0.76	0.80	-4.7	+2.3	+5.3	-0.6	+0.8	-3.5	+3.3	+3.6	+4.1	17.4	17.4	17.7	(676)	(802)	(929)	(1.2)	(1.4)	(1.5)	-26.8	-28.7	-9.8
Coach, Inc. (NR)	Dec.	1.88	2.12	2.34	-1.9	+12.6	+10.4							16.7	18.1	18.7							+6.1	-7.2	-2.1
Hermès International (=)	Dec.	9.73	10.65	11.74	+18.8	+9.4	+10.3	+1.7	-1.6	-1.7	+8.6	+9.7	+9.7	31.7	32.0	32.2	(1,974)	(2,627)	(3,349)	(1.1)	(1.4)	(1.6)	-11.1	+6.5	-3.3
Hugo Boss (+)	Dec.	5.23	5.45	5.66	+3.7	+4.2	+3.8	+7.1	+4.4	+0.7	+2.2	+4.7	+4.0	17.2	17.3	17.3	79	72	59	0.1	0.1	0.1	-34.0	-29.6	-8.7
Jimmy Choo PLC (NR)	Dec.	0.05	0.07	0.08	-12.6	+22.2	+21.5							10.4	10.9	11.4							-16.4	-28.1	-18.4
Kering (+)	Dec.	9.77	11.24	12.78	-23.2	+15.1	+13.7	+9.8	+7.2	+7.6	+5.5	+6.3	+5.9	15.6	16.7	17.4	3,972	3,347	2,509	1.9	1.4	1.0	-10.2	-9.2	-9.5
LVMH (=)	Dec.	7.74	8.68	9.26	+22.8	+12.1	+6.6	+3.8	+3.4	+0.6	+6.0	+5.9	+5.9	18.7	19.9	19.9	3,112	1,045	(965)	0.4	0.1	(0.1)	-16.1	+5.9	-6.6
Michael Kors Holdings (NR)	Dec.	4.34	4.41	4.68	+1.3	+1.8	+6.1							25.3	23.9	23.6							-10.0	-41.5	-5.4
Moncler (=)	Dec.	0.67	0.78	0.83	+28.1	+16.3	+7.4	+0.7	+3.2	-1.1	+19.5	+13.4	+8.1	29.7	29.9	29.7	3	(126)	(266)	0.0	(0.4)	(0.7)	-23.2	+12.5	-4.4
Mulberry Group PLC (NR)	Dec.	0.06	0.13	0.25		+109.5	+93.7							3.6	5.5	8.1							+5.6	+19.7	+0.1
Prada (=)	Jan.	0.15	0.17	0.19	-17.4	+14.2	+8.6	+1.4	+8.0	+7.2	-6.1	+3.3	+4.6	16.1	17.5	18.1	(262)	(431)	(610)	(0.3)	(0.4)	(0.6)	-32.7	-44.3	-11.6
Ralph Lauren Corp Class A (NR)	Dec.	6.94	7.82	8.80	-12.0	+12.7	+12.5							11.7	12.2	12.8					<b></b>	(a =)	-11.2	-36.4	-6.9
Salvatore Ferragamo (+)	Dec. Dec.	0.97 3.44	1.11 3.93	1.16 4.20	+2.0 +8.3	+14.7 +14.3	+5.2 +7.0	-1.9 +4.1	-3.4 +6.4	-7.2 +4.5	-1.0 +2.6	+4.9 +4.0	+4.0 +6.5	17.5 14.9	18.4 15.9	18.6 15.9	(11) (165)	(100) (207)	(195) (248)	(0.0)	(0.3)	(0.5)	-23.8 -12.9	-2.3 -2.8	-8.1 -5.5
Tod's (-)	Dec.	3.44	3.93	4.20	+0.3	+14.3	+7.0	+4.1	+0.4	+4.5	+2.0	+4.0	+0.5	14.9	15.9	15.9	(100)	(207)	(240)	(0.0)	(0.9)	(1.0)	-12.9	-2.0	-5.5
Characteristics for the second state of the se	D	0.40	0.45	0.50	-27.7	.40.4	. 44. 4							0.0	0.0	0.0							-22.2	-48.2	
Chow Tai Fook Jewellery Group Ltd (NE)	Dec.	0.40	0.45	0.50	-27.7 -40.0	+13.4	+11.4							8.3	8.9	9.3 2.6							-22.2 -22.6		-5.5
Emperor Watch & Jewellery Ltd (NR)	Dec. Dec.	0.01 0.11	(0.00)	0.02	-40.0	NS +4.9	NS +13.0							1.9	(1.2) 6.3	6.6							-22.6 -4.1	-47.5 -23.1	-6.1 -9.7
Hengdeli Holdings Ltd (NR)		2.06	2.20	2.43	-15.3	+4.9	+10.4							6.1	10.6	11.1							-4.1 -19.3	-23.1 -42.3	-9.7 -7.6
Luk Fook Holdings International Ltd (N Richemont (+)	Dec. Mar.	3.72	4.06	4.42	+7.3	+9.2	+10.4	+0.5	+6.2	+5.5	+2.8	+4.3	+4.9	10.2 23.0	23.4	24.1	(5,520)	(6,635)	(7,776)	(1.8)	(1.9)	(2.1)	-19.3	-42.3 -17.4	-8.6
Swatch Group B (=)	Dec.	23.09	25.73	27.62	-9.4	+11.4	+7.4	+3.5	+3.1	+1.2	+2.0	+4.3	+4.9	18.7	23. <del>4</del> 19.1	19.7	(5,520)	(2,541)	(3,212)	(0.8)	(1.9)	(1.4)	-19.4	-17.4	-10.3
Tiffany & Co (NR)	Jan.	3.94	4.30	5.33	-5.2	+11.4	+24.1	+3.3	+3.1	T1.2	+3.1	T4.1	T4. I	19.6	20.3	20.9	(1,579)	(4,541)	(3,212)	(0.0)	(1.2)	(1.4)	-19.5	-20.1 -28.7	-10.3
Eyewear	our.	0.04	1.00	0.00	0.2	, 0.0								10.0	20.0	20.0							10.1	20.7	10.0
Luxottica (=)	Dec.	2.01	2.18	2.47	+30.6	+8.6	+13.2	+8.9	+4.9	+5.9	+8.2	+7.9	+8.1	17.6	17.9	18.3	710	117	(600)	0.4	0.1	(0.3)	-7.7	+23.9	-5.7
Safilo (NR)	Dec.	0.48	0.81	0.51	-32.7	+70.4	-36.9	10.3	17.3	10.3	10.2	11.3	10.1	5.6	6.9	5.5	, 10	117	(000)	U. <del>1</del>	0.1	(0.0)	-16.3	-8.7	-8.6
	200.	00	0.01	0.01	0=.1		55.0							0.0	0.0	0.0							. 0.0	0	0.0

### **DISCLOSURES**

### **Analyst Certification**

We, Melania Grippo, Guido Lucarelli, Luca Solca, (authors of or contributors to the report) hereby certify that all of the views expressed in this report accurately reflect our personal view(s) about the company or companies and securities discussed in this report. No part of our compensation was, is, or will be, directly, or indirectly, related to the specific recommendations or views expressed in this research report.

### Non-US Research Analyst Disclosure

The research analysts named below were involved in preparing this research report. Research analysts at Exane Ltd and Exane SA are not associated persons of Exane Inc. and thus are not registered or qualified in the U.S. as research analysts with the Financial Industry Regulatory Authority (FINRA) or the New York Stock Exchange (NYSE). These non-U.S. analysts are not subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Melania Grippo (Exane SA), Guido Lucarelli (Exane SA), Luca Solca (Exane SA)

Exane SA is regulated by the Autorité des Marchés Financiers (AMF) in France, Exane Ltd is authorised and regulated by the Financial Conduct Authority in the United Kingdom, and Exane Inc. is regulated by FINRA and the U.S. Securities and Exchange Commission in the United States.

### **Research Analyst Compensation**

The research analyst(s) responsible for the preparation of this report receive(s) compensation based upon various factors including overall firm revenues, which may include investment banking activities.

### Disclosure of the report to the company/ies

Companies Disclosures NONE

- 1 Sections of this report, with the research summary, target price and rating removed, have been presented to the subject company/ies prior to its distribution, for the sole purpose of verifying the accuracy of factual statements.
- 2 Following the presentation of sections of this report to this subject company, some conclusions were amended.

#### **Definitions**

For an explanation of definitions used in Exane research reports, please see the glossary at https://www.exane.com/jsp/action/commun/JSPacLexique.jsp

### Commitment to transparency on potential conflicts of interest: BNP Paribas

While BNP Paribas ("BNPP") holds a material ownership interest in the various Exane entities, Exane and BNPP have entered into an agreement to maintain the independence of Exane's research reports from BNPP. These research reports are published under the brand name "Exane BNP Paribas". Nevertheless, for the sake of transparency, we separately identify potential conflicts of interest with BNPP regarding the company/(ies) covered by this research document.

The latest company-specific disclosures, valuation methodologies and risks to investment case are available on www.exane.com/toolbox/compliance if they are not in this document.

### **EXANE BNP PARIBAS**

Analyst location: As per contact details, analysts are based in the following locations: London, UK for telephone numbers commencing +44; Paris, France +33; Frankfurt, Germany +49; Geneva, Switzerland +41; Madrid, Spain +34; Milan, Italy +39; New York, USA +1; Singapore +65; Stockholm, Sweden +46.

Important notice: Please refer to our complete compliance page available on www.exane.com/compliance that includes Exane's policy for managing conflicts of interest, Rating definitions and complete disclosures per company.

Exane is independent of BNP Paribas (BNPP) and the agreement between the two companies is structured to guarantee the independence of Exane's research, published under the brand name "Exane BNP Paribas". Nevertheless, to respect a principle of transparency, we separately identify potential conflicts of interest with BNPP regarding the company/(ies) covered by this research document.

This research is produced by one or more of EXANE SA, EXANE Limited and Exane Inc (collectively referred to as "EXANE"). EXANE SA is authorized by the Autorité de Contrôle Prudentiel et de Résolution and regulated by the Autorité des Marchés Financiers ("AMF"). EXANE Limited is authorized and regulated by the Financial Conduct Authority. Exane Inc is registered and regulated by the Financial Industry Regulatory Authority ("FINRA"). In accordance with the requirements of Financial Conduct Authority COBS 12.2.3R and associated guidance, of article 313-20 of the AMF Règlement Général, and of FINRA Rule 2711, Exane's policy for managing conflicts of interest in relation to investment research is published on Exane's web site (www.exane.com). Exane also follows the guidelines described in the code of conduct of the Association Francaise des Entreprises d'Investissement ("AFEI") on managing conflicts of interest in the field of investment research. This code of conduct is available on Exane's web site (www.exane.com).

This research is solely for the private information of the recipients. All information contained in this research report has been compiled from sources believed to be reliable. However, no representation or warranty, express or implied, is made with respect to the completeness or accuracy of its contents, and it is not to be relied upon as such. Opinions contained in this research report represent Exane's current opinions on the date of the report only. Exane is not soliciting an action based upon it, and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of any offer to buy.

While Exane endeavours to update its research reports from time to time, there may be legal and/or other reasons why Exane cannot do so and, accordingly, Exane disclaims any obligation to do so.

This report is provided solely for the information of professional investors who are expected to make their own investment decisions without undue reliance on this report and Exane accepts no liability whatsoever for any direct or consequential loss arising from any use of this report or its contents.

ANALYST CERTIFICATION: all of the views expressed in the research report accurately reflect the research analyst's personal views about any and all of the subject securities or issuers of this research report. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the research analyst in this research report.

This report may not be reproduced, distributed or published by any recipient for any purpose. Any United States person wishing to obtain further information or to effect a transaction in any security discussed in this report should do so only through Exane Inc., which has distributed this report in the United States and, subject to the above, accepts responsibility for its contents.

BNP PARIBAS has acquired an interest in VERNER INVESTISSEMENTS the parent company of EXANE. VERNER INVESTISSEMENTS is controlled by the management of EXANE. BNP PARIBAS's voting rights as a shareholder of VERNER INVESTISSEMENTS will be limited to 40% of overall voting rights of VERNER INVESTISSEMENTS.

Exane BNP Paribas research is also available on the website (www.exanebnpparibas-equities.com) as well as on Bloomberg (EXEQ), First Call, Reuters and Capital IQ.

### LONDON

Exane Ltd 1 Hanover Street London W1S 1YZ UK

Tel: (+44) 207 039 9400

### **FRANKFURT**

Branch of Exane S.A. Europa-Allee 12, 3rd floor D.60327 Frankfurt Germany

Tel: (+49) 69 42 72 97 300

#### **MADRID**

Branch of Exane S.A. Calle Serrano 73 28006 Madrid Spain

Tel: (+34) 91 114 83 00

### **NEW YORK**

Exane Inc. 640 Fifth Avenue 15th Floor New York, NY 10019 USA

Tel: (+1) 212 634 4990

### **STOCKHOLM**

Representative office of Exane SA Nybrokajen 5 111 48 Stockholm Sweden

Tel: +46 8 5629 3500

### **PARIS**

Exane S.A. 16 Avenue Matignon 75008 Paris France

Tel: (+33) 1 44 95 40 00

### **GENEVA**

Branch of Exane S.A. Rue du Rhône 80 1204 Geneva Switzerland

Tel: (+41) 22 718 65 65

#### MILAN

Branch of Exane S.A. Via dei Bossi 4 20121 Milan Italy

Tel: (+39) 02 89631713

### **SINGAPORE**

Branch of Exane Ltd 20 Collyer Quay #07-02 Tung Centre Singapore 049319 Tel: (+65) 6212 9059